TOKYO - (JCN Newswire) - Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer and more fulfilling, today announced publication of the EAGLE Trial1 - a multicenter randomized controlled study evaluating the CADDIE(TM) device, the first cloud-based Computer-Aided Detection (CADe) application for real-time polyp detection during colonoscopy that is both FDA-cleared and CE-marked. The CADDIE software is the first solution introduced as part of the OLYSENSE(TM) Intelligent Endoscopy Ecosystem.The trial indicates that cloud-deployed AI can help endoscopists detect the lesions that matter most in preventing progression to cancer2-5 - large adenomas, particularly those flat in morphology, and sessile serrated lesions (SSLs) - without disrupting safety or workflow. The study has been published in npj Digital Medicine.1
EAGLE Trial Overview
The EAGLE (Evaluation of AI for detection of Gastrointestinal Lesions in Endoscopy) study was conducted across eight centers in four European countries6, and its primary analysis involved 841 patients and 22 endoscopists performing screening and surveillance colonoscopies. Patients were randomized to standard colonoscopy or CADDIE-assisted colonoscopy.
Key Findings
- Improved detection of high-risk and hard-to-detect lesions
In screening and surveillance patients, use of the CADDIE(TM) application was associated in this study with 7.3% absolute increase in adenoma detection rate (ADR), compared to standard colonoscopy. Moreover, significant relative increases in lesions detected per colonoscopy were observed in this study for clinically relevant lesion subtypes: 93% for large (>10 mm) adenomas, 57% for non-polyploid adenomas and 230% for SSLs.
- Feasible and efficient real-time cloud-based deployment
The system demonstrated real-time performance and operational efficiency across diverse testing environments.
Clinically Relevant by Design
The CADDIE(TM) application is trained on a dataset enriched in clinically relevant and hard-to-detect lesions, including flat sessile serrated lesions (SSLs) and large polyps.
Lesions with sessile or flat morphology are difficult to detect and can harbor clinically relevant pathology. SSLs, in particular, are high-risk lesions whose detection is critical to reducing the risk of post-colonoscopy colorectal cancer3-4. The ability to reliably detect SSLs is increasingly viewed as a critical quality consideration in colonoscopy7. This study demonstrates increased detection of clinically relevant lesions and no increase in unnecessary resections, addressing some of the concerns raised in recent guidelines8-9.
Press release: https://acnnewswire.com/press-release/english/104804/